New kidney pill aims to cut protein leak in diabetics
NCT ID NCT07667517
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug finerenone can reduce protein in the urine (a sign of kidney damage) in adults with type 2 diabetes and chronic kidney disease. About 148 participants will receive either finerenone or a placebo pill daily for 6 months, on top of their usual medications. The main goal is to see if more people on finerenone achieve a meaningful drop in urine protein levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
finerenone (a pill that blocks a hormone to protect the kidneys)
What this could lead to
If it works, finerenone could become a standard add-on treatment to help slow kidney damage and reduce protein leakage in people with diabetes.
What could go wrong
This is a Phase 4 trial with only 148 people, so results may not apply to everyone. Finerenone can raise potassium levels, which requires careful monitoring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Provincial Hospital
Fuzhou, Fujian, China
Contact Phone: •••-•••-••••
-
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
Contact Phone: •••-•••-••••
-
Nantong First People's Hospital
Nantong, Jiangsu, China
Contact Phone: •••-•••-••••
-
Sanshui Hospital, Zhujiang Hospital, Southern Medical University
Foshan, Guangdong, China
Contact Phone: •••-•••-••••
-
Shanghai Municipal Hospital of Traditional Chinese Medicine
Shanghai, Shanghai Municipality, China
Contact Phone: •••-•••-••••
-
Suzhou Science and Technology City Hospital
Suzhou, Jiangsu, China
Contact Phone: •••-•••-••••
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Contact Phone: •••-•••-••••
-
The First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, China
Contact Phone: •••-•••-••••
-
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Contact Phone: •••-•••-••••
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First People's Hospital of Suqian
Suqian, Jiangsu, China
Contact Phone: •••-•••-••••
-
Xi'an Daxing Hospital
Xi'an, Shaanxi, China
Contact Phone: •••-•••-••••
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Contact Phone: •••-•••-••••